Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Baburajendran

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Neuron|April 25, 2020
Loss of PYCR2 Causes Neurodegeneration by Increasing Cerebral Glycine Levels via SHMT2Nathalie Escande-Beillard, Abigail Loh, Sahar N Saleem, et al.
Angewandte Chemie (International Ed. in English)|May 19, 2021
Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*David Quach, Guanghui Tang, Jothi Anantharajan, et al.
Protein Science : a Publication of the Protein Society|November 11, 2021
Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphataseJothi Anantharajan, Nithya Baburajendran, Grace Lin, et al.
Bioorganic & Medicinal Chemistry|October 2, 2021
Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitorsPearly Shuyi Ng, Klement Foo, Sandra Sim, et al.
Molecular Cancer Therapeutics|July 10, 2019
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer CellsJothi Anantharajan, Hengbo Zhou, Lingdi Zhang, et al.
Journal of Medicinal Chemistry|January 8, 2020
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2Jacek Kwiatkowski, Boping Liu, Shermaine Pang, et al.
Journal of Medicinal Chemistry|August 7, 2025
Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 M<sup>pro</sup> Inhibitor with Pan-Coronavirus ActivityQian Wen Tan, Subramanyam Vankadara, Jia Yi Fong, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3"Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Journal of Medicinal Chemistry|December 23, 2025
Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 M<sup>pro</sup> Inhibitor with Pan-Coronavirus Activity"Qian Wen Tan, Subramanyam Vankadara, Jia Yi Fong, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Neuron|April 25, 2020
Loss of PYCR2 Causes Neurodegeneration by Increasing Cerebral Glycine Levels via SHMT2Nathalie Escande-Beillard, Abigail Loh, Sahar N Saleem, et al.
Angewandte Chemie (International Ed. in English)|May 19, 2021
Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*David Quach, Guanghui Tang, Jothi Anantharajan, et al.
Protein Science : a Publication of the Protein Society|November 11, 2021
Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphataseJothi Anantharajan, Nithya Baburajendran, Grace Lin, et al.
Bioorganic & Medicinal Chemistry|October 2, 2021
Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitorsPearly Shuyi Ng, Klement Foo, Sandra Sim, et al.
Molecular Cancer Therapeutics|July 10, 2019
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer CellsJothi Anantharajan, Hengbo Zhou, Lingdi Zhang, et al.
Journal of Medicinal Chemistry|January 8, 2020
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2Jacek Kwiatkowski, Boping Liu, Shermaine Pang, et al.
Journal of Medicinal Chemistry|August 7, 2025
Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 M<sup>pro</sup> Inhibitor with Pan-Coronavirus ActivityQian Wen Tan, Subramanyam Vankadara, Jia Yi Fong, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3"Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Journal of Medicinal Chemistry|December 23, 2025
Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 M<sup>pro</sup> Inhibitor with Pan-Coronavirus Activity"Qian Wen Tan, Subramanyam Vankadara, Jia Yi Fong, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Pageof 2